Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile
Giovanni Marchegiani

@gio_marchegiani

Pancreas Surgeon @UniPadova 😷 @BJSOpen Editor 🗞️ @ISGPS_news Secretary 🎓 @YouppiePancreas Coordinator @EAHPBA board 🪡@MGHSurgery @PancreasVerona trained

ID: 948112554882199552

linkhttp://www.linkedin.com/in/giovanni-marchegiani-930850ab/ calendar_today02-01-2018 08:43:42

1,1K Tweet

9,9K Followers

677 Following

Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

What a kickoff of #EPC2024 in Santiago 🇪🇸 as it can’t get more emotional than commemorating Claudio Bassi 👑 and his legacy with Roberto Salvia and Marc Besselink Keep rocking and guiding us from up there, Bifo! 🎸🎸🎸

What a kickoff of #EPC2024 in Santiago 🇪🇸 as it can’t get more emotional than commemorating Claudio Bassi 👑 and his legacy with <a href="/SalviaRobi/">Roberto Salvia</a> and <a href="/MarcBesselink/">Marc Besselink</a> 

Keep rocking and guiding us from up there, Bifo! 🎸🎸🎸
Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

Postoperative acute pancreatitis at EPC-Europ Pancr Club 🇮🇹 🇫🇮 🇺🇸 international panel debate 👹 Risk factor soft pancreas rich in acini 💦 Fluid management in OR is key 🧪 Check your amylase in first 48 hours 📛 Label patients with POH applying “No rush after surgery policy” 😂

Postoperative acute pancreatitis at <a href="/EurPancClub/">EPC-Europ Pancr Club</a> 🇮🇹 🇫🇮 🇺🇸 international panel debate 

👹 Risk factor soft pancreas rich in acini 

💦 Fluid management in OR is key 

🧪 Check your amylase in first 48 hours 

📛 Label patients with POH applying “No rush after surgery policy” 😂
Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

Do you know Intraductal Oncocytic Pancreatic Neoplasms 🍇 ?! IOPN have distinct features 🫧 M:F 1.5: 1 / median size 50 mm / more frequent in the head 📈 50% are invasive / good long term survival 🧬 Classic pancreatic drivers less altered! modernpathology.org/article/S0893-…

Do you know Intraductal Oncocytic Pancreatic Neoplasms 🍇 ?! 

IOPN have distinct features 

🫧 M:F 1.5: 1 / median size 50 mm / more frequent in the head 

📈 50% are invasive / good long term survival 

🧬 Classic pancreatic drivers less altered! 

modernpathology.org/article/S0893-…
Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

Friends like Ajay Maker 🇺🇸 can indeed inspire your days! What is the role of immunity 🦹 in the development of IPMN?! Can we halt / predict their evolution ?! 🧬 A lot is going on… stay tuned!

Friends like <a href="/Maker_MD/">Ajay Maker</a> 🇺🇸 can indeed inspire your days! 

What is the role of immunity 🦹 in the development of IPMN?! Can we halt / predict their evolution ?!

🧬 A lot is going on… stay tuned!
Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

Minimally invasive Pancreatoduodenectomy 🎯How to guide patient selection?! 🧐 🚦 Complexity and Experience grading from ISGPS 👍 Patient factors include anatomy, vascular contact, conditional 🏥 Surgeon + center annual MIPD experience 👉journals.lww.com/annalsofsurger…

Minimally invasive Pancreatoduodenectomy 🎯How to guide patient selection?! 🧐

🚦 Complexity and Experience grading from <a href="/ISGPS_news/">ISGPS</a> 

👍 Patient factors include anatomy, vascular contact, conditional 

🏥 Surgeon + center annual MIPD experience

👉journals.lww.com/annalsofsurger…
Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

👈🤔👉 Which direction to take in this MD-IPMN 🍇 resection ?! 👔 Lesion is in the neck/ proximal body 🌱 The CHA is totally replaced from the SMA … 🔦 Would you perform intraoperative pancreatoscopy?! 🙋‍♂️ Extended PD / extended distal / neither of them?!

Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

🇯🇵 Mastering the dissection of the first jejunal branches during pancreatoduodenctomy 🏣 Japanese surgeons secret weapon: sketching the anatomy of each case before surgery!

🇯🇵 Mastering the dissection of the first jejunal branches during pancreatoduodenctomy 

🏣 Japanese surgeons secret weapon: sketching the anatomy of each case before surgery!
Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

🤖 Robotic pancreatoduodenectomy with multiple scope transition by YosukeInoueHPB 🇯🇵 🦾 First approach the SMA from the left 🔄 Then move to central position and finally right with port hopping 🥷 Amazing skills and a true honor to be invited to deliver lectures!

🤖 Robotic pancreatoduodenectomy with multiple scope transition by <a href="/YosukeInoueHPB/">YosukeInoueHPB</a> 🇯🇵 

🦾 First approach the SMA from the left

🔄 Then move to central position and finally right with port hopping 

🥷 Amazing skills and a true honor to be invited to deliver lectures!
Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

👩‍🚀 Houston: we have a problem! 🪐 🚨 The ISGPS definitions of complications suffer for significant interobserver variability 🙉 13 centers - 68% agreement 🙈 🏥 Within centers increase to 84% 💡Efforts / new tools needed! 👉journals.lww.com/annalsofsurger…

👩‍🚀 Houston: we have a problem! 🪐

🚨 The <a href="/ISGPS_news/">ISGPS</a> definitions of complications suffer for significant interobserver variability

🙉 13 centers - 68% agreement 🙈 

🏥 Within centers increase to 84%

💡Efforts / new tools needed! 

👉journals.lww.com/annalsofsurger…
Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

Surgery for non functioning pancreatic neuroendocrine tumors 🍇 Are we harming our patients !? 🤔 🔎 Almost 400 resected P-NET with path and FU analysis 4⃣0⃣% Inadequate treatment (34% potential overtreatment) 🔮 Size only reliable predictor❗️ 👉academic.oup.com/bjsopen/articl…

Surgery for non functioning pancreatic neuroendocrine tumors 🍇 Are we harming our patients !? 🤔

🔎 Almost 400 resected P-NET with path and FU analysis 

4⃣0⃣% Inadequate treatment (34% potential overtreatment)

🔮 Size only reliable predictor❗️

👉academic.oup.com/bjsopen/articl…
Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

POPF risk classification 🚨 The easier the better!? 🧐 Prospective validation of ISGPS system on 300 PD segregates 4 classes of POPF A🪨📐 9% B🪨🤏 11% C 🧈📐 20% D 🧈🤏 37% independent risk factor! 🤔 How do you assess POPF risk?! journals.lww.com/annalsofsurger…

POPF risk classification 🚨 The easier the better!?

🧐 Prospective validation of <a href="/ISGPS_news/">ISGPS</a> system on 300 PD segregates 4 classes of POPF

A🪨📐 9%
B🪨🤏 11%
C 🧈📐 20%
D 🧈🤏 37%  independent risk factor! 

🤔 How do you assess POPF risk?! 

journals.lww.com/annalsofsurger…
Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

🧞‍♂️The Henle’s trunk - a top player in pancreas surgery! ☘️ Can you name the 3 main tributaries and most common variations ?! Important to prevent intraoperative bleeding 👉👈 and it’s where pancreas and GI surgery meet…

🧞‍♂️The Henle’s trunk - a top player in pancreas surgery! 

☘️ Can you name the 3 main tributaries and most common variations ?! Important to prevent intraoperative bleeding 

👉👈 and it’s where pancreas and GI surgery meet…
Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

The dilemma of MPD dilatation after PD for non invasive IPMN 🍇 ... Keep calm! 🧐 481 multicentric resections 🤏 27% MPD dilated after a median of 3 years 🔮 Age at PD and FU duration only predictors... 🔪 Completion surgery 3% / malignancy 0.8% 👉journals.lww.com/annalsofsurger…

The dilemma of MPD dilatation after PD for non invasive IPMN 🍇 ... Keep calm! 

🧐 481 multicentric resections 🤏 27% MPD dilated after a median of 3 years

🔮 Age at PD and FU duration only predictors... 

🔪 Completion surgery 3% / malignancy 0.8%
 
👉journals.lww.com/annalsofsurger…
Giovanni Marchegiani (@gio_marchegiani) 's Twitter Profile Photo

🎉 Finally a “Neoadjuvant” therapy for non functioning pancreatic NET 🦓 🇮🇹 Multicenter phase 2 study with 177Lu-DOTATATE on p-NET at high risk for recurrence 👍 Acceptable complications / no postop death / no disease progression 🏅Landmark paper! 👉academic.oup.com/bjs/article/11…

🎉 Finally a “Neoadjuvant” therapy for non functioning pancreatic NET 🦓 

🇮🇹 Multicenter phase 2 study with 177Lu-DOTATATE on p-NET at high risk for recurrence 

👍 Acceptable complications / no postop death / no disease progression

🏅Landmark paper! 

👉academic.oup.com/bjs/article/11…